HOME >> MEDICINE >> NEWS
Pfizer's VFEND(R) receives FDA approval for treatment of esophageal candidiasis

NEW YORK, November 17, 2003 - Pfizer Inc said today that it has received U.S. Food and Drug Administration (FDA) approval to market VFEND (voriconazole), a broad spectrum antifungal medicine, for the treatment of esophageal candidiasis.

Candida organisms are normally found on skin and mucous membranes in healthy individuals, but in persons whose immune systems are weakened or compromised by cancer chemotherapy, organ transplants or HIV/AIDS, Candida can multiply causing potentially serious infections. In immunocompromised patients, esophageal candidiasis may coat much of the surface of the mouth resulting in pain and difficulty swallowing and may ultimately progress to more serious, invasive disease.

The basis for the approval of VFEND to treat esophageal candidiasis infections was a clinical trial with immunocompromised patients conducted at study sites in 15 countries. All patients had a proven diagnosis of esophageal candidiasis and most of the patients also had additional underlying diseases, such as hematologic malignancies, chronic obstructive pulmonary disease (COPD) and AIDS.

Patients received either VFEND or fluconazole. Those treated with VFEND had success rates of 98 percent compared to 95 percent for fluconazole. Both VFEND and fluconazole had acceptable tolerability and safety. VFEND was discovered by Pfizer researchers and was developed to address the unmet medical need for more effective and better-tolerated options for patients with invasive aspergillosis and other serious fungal infections.

Initially, VFEND was approved in the U.S. for the primary treatment of acute invasive aspergillosis and salvage therapy for rare but serious fungal infections caused by the pathogens Scedosporium apiospermum and Fusarium spp. VFEND can be administered both orally and intravenously. Pfizer is continuing to study VFEND for the treatment of serious fungal infections.

In clinical trials, the most common adverse
'"/>

Contact: Susan Yarin
susan.yarin@pfizer.com
212-733-5260
Edelman Public Relations
17-Nov-2003


Page: 1 2

Related medicine news :

1. FDA approves Pfizers Lyrica for the treatment of the two most common forms of neuropathic pain
2. Pfizers antifungal medicine VFEND receives FDA approval
3. New data sets survival benchmark for Pfizers ELLENCE
4. Pfizers VFEND (R) as effective in treating Candidemia as two-drug standard of care, study shows
5. Pfizers ZYVOX(TM) more effective than vancomycin in treating complicated SSTIs caused by MRSA
6. UIC professor receives international humanitarian award
7. Mailman School of Public Health receives Manhattan Tobacco Cessation Center grant
8. Epidemiologist Trichopoulos receives $5.8 million Department of Defense Innovator Award
9. GlaxoSmithKline receives unanimous favorable recommendation by FDA Advisory Committee for Boostrix
10. NYU Child Study Center receives grant from the American Red Cross September 11 recovery program
11. Northwestern Memorial Hospital receives $10 million commitment to support preeminent heart program

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/22/2017)... ... September 22, 2017 , ... ... Pennsylvania, is pleased to offer in-home and online newborn sleep consultations . ... has on the body,” says company owner Courtney Zentz, a pediatric sleep professional, ...
(Date:9/22/2017)... ... ... “Cursed with a Curse: The Truth about Tithing”: a ... when breaking free from this misconception. “Cursed with a Curse: The Truth about ... Christian Faith Publishing, Lysa M. Harrison’s new book is a powerful and thought-provoking ...
(Date:9/22/2017)... ... 22, 2017 , ... Silicon Valley startup Enke Life has ... Their electric toothbrushes aggressively attack oral bacteria by reducing dental plaque and other ... edge Enke technology with a premium timeless design, they want to redefine the ...
(Date:9/22/2017)... ... September 22, 2017 , ... Egg freezing and embryo ... embryos have a slight statistical advantage for live births, frozen eggs offer many ... for women undergoing medical treatment or who are concerned about the decline of ...
(Date:9/21/2017)... ... September 21, 2017 , ... Process ... 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/processcapabilityindices      , ... wrong, run afoul of The Quality System Regulation (§820.250), and Devicemakers find themselves ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... 7, 2017  Eli Lilly and Company (NYSE: ... streamline operations to more efficiently focus resources on ... structure. Global workforce reductions, including those from a ... impact approximately 3,500 positions. With ... savings of approximately $500 million that will begin ...
(Date:9/7/2017)... Ind. , Sept. 7, 2017  Zimmer Biomet ... in musculoskeletal healthcare, today announced that it will be ... Global Healthcare Conference at the Grand Hyatt hotel in ... 11, 2017 at 11:40 a.m. Eastern Time. ... via Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com ...
(Date:9/6/2017)... ORANGEBURG, N.Y. , Sept. 6, 2017   PDI ... today announced it will host an educational session focused ... line-associated bloodstream infection (CLABSI) prevention at the 2017 Annual ... meeting, which will take place at the ... Arizona from Sept. 16-19, will also feature ...
Breaking Medicine Technology:
Cached News: